BioMarin reports Q2 adjusted EPS 6c, consensus (42c) Reports Q2 revenue $191.7M, consensus $158.96M. The increased non-GAAP net income for Q2 compared to the second quarter of 2013 was primarily due to strong uptake of VIMIZIM in its first full quarter of commercial sales, and significant growth in revenues from other commercial products including, Naglazyme, KUVAN, Aldurazyme and Firdapse. VIMIZIM sales topped $14M in first full quarter of sales.
News For BMRN From The Last 14 Days
Check below for free stories on BMRN the last two weeks.